Instructions for submitting changes and for reporting during the course of a clinical trial

<table>
<thead>
<tr>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>In general</td>
<td>2</td>
</tr>
<tr>
<td>Submission forms</td>
<td>2</td>
</tr>
<tr>
<td>Changes during the conduct of a clinical trial (amendments) (Art. 34 ClinO)</td>
<td>3</td>
</tr>
<tr>
<td>Protocol Amendments related to the use and/or safety of the IMP (Section 5 of the CTA dossier)</td>
<td>4</td>
</tr>
<tr>
<td>Changes to the pharmaceutical quality documentation (PQD) of the IMP (Section 7 of the CTA dossier)</td>
<td>4</td>
</tr>
<tr>
<td>Changes to Study Medication Labels (Section 9 of the CTA dossier)</td>
<td>6</td>
</tr>
<tr>
<td>Updated Investigator’s Brochure (IB) (Section 6 of the CTA dossier)</td>
<td>6</td>
</tr>
<tr>
<td>Change of Sponsor / Sponsor Name or Address / other administrative changes (Section 2 of the CTA dossier)</td>
<td>6</td>
</tr>
<tr>
<td>Change Swiss Representative/ Representative Name or Address / other administrative changes (Section 2 of the CTA dossier)</td>
<td>7</td>
</tr>
<tr>
<td>Safety reporting in clinical trials of the categories B and C (Art. 37 ClinO)</td>
<td>7</td>
</tr>
<tr>
<td>Premature discontinuation / Trial interruption</td>
<td>7</td>
</tr>
<tr>
<td>Beginning and end of the trial</td>
<td>8</td>
</tr>
<tr>
<td>Final clinical study report</td>
<td>8</td>
</tr>
</tbody>
</table>
1 In general

These instructions concern changes and reporting related exclusively to clinical trials of Category B and C.

Points to consider:

Incomplete dossiers will not be processed but returned. Please only submit documents that are complete and ready for processing.

All documents (including submission forms) have to be submitted as paper copy (where requested as explained below in track change mode or with visible changes, otherwise as clean version) AND as an electronic copy e.g. on CD-ROM (clean version for all documents and where requested as explained below additionally in track change mode or with visible changes).

If not specified otherwise, all documents must be submitted as long as they cover the time period until study end in Switzerland is reached.

An updated CTA-form needs to be submitted only when additional IMPs are introduced with an Amendment.

2 Submission forms

The following original signed forms must be used:

A. Changes to a running trial according to chapters 3 to 9 of this document
   - Form BW101_10_004e_FO Submission of Changes to a Clinical Trial
     Title: Submission of Changes to a Clinical Trial and Answer to Conditions
     Available on our web page under www.swissmedic.ch > Human medicines > Clinical trials on medicinal products > Submission of changes and reporting > Guidelines and Forms

B. Reporting related to a trial and trial completion according to chapters 10 to 13 of this document
   - Form BW101_10_005e_FO Reporting Related to a Clinical Trial
     Title: Reporting Related to a Clinical Trial
     Available on our web page under www.swissmedic.ch > Human medicines > Clinical trials on medicinal products > Submission of changes and reporting > Guidelines and Forms

C. Answers to conditions made by Swissmedic
   - Form BW101_10_004e_FO Submission of Changes to a Clinical Trial
     Title: Submission of Changes to a Clinical Trial and Answer to Conditions
     Available on our web page under www.swissmedic.ch > Human medicines > Clinical trials on medicinal products > Submission of changes and reporting > Guidelines and Forms

D. Administrative Changes (including change of sponsorship and Swiss representative)
   - Form BW101_00_001e_FO Administrative Changes
     Title: Administrative Changes (incl.sponsorship and Swiss rep.)
     Available on our web page under www.swissmedic.ch > Human medicines > Clinical trials on medicinal products > Submission of changes and reporting > Guidelines and Forms
E. SUSARs

- CIOMS forms (international standard)
- Form BW101_20_001e_FO Accompanying form for SUSARs
  Title: Accompanying Form SUSAR
- Available on our web page under www.swissmedic.ch > Human medicines > Clinical trials on medicinal products > Safety measures in clinical trials > Instructions and forms
- Please consult our information sheet Safety Relating to Clinical Trials – Compulsory notification under www.swissmedic.ch > Human medicines > Clinical trials on medicinal products > Safety measures in clinical trials > Instructions and forms.

**IMPORTANT information on the above-listed topics A-C:**

- A document related to several clinical trials can be submitted using a single submission form. However, a separate form must be used for each sponsor representative. The clinical trial(s) must be clearly identified with their Swissmedic reference numbers.

- **Please do not send any cover letter.** If this cannot be avoided due to the necessity of providing relevant information which cannot be included in the submission form, please list this letter as a document in the form (S10 of form "Submission of Changes to a Clinical Trial and Answer to Conditions” / R1 of form "Reporting Related to a Clinical Trial)

- Always give a short and precise introduction on the content of the submitted change of each document listed. This introduction has to be given in the section 2: Rationale / Information of the submission form ("Submission of Changes to a Clinical Trial" or "Reporting Related to a Clinical Trial").

- All documents related to the notified changes or reporting have to be listed on the submission form in the corresponding field. If several documents are submitted for the same section of the CTA dossier, additional lines must be added for the corresponding section of the CTA dossier. Incomplete or not correctly filled forms will not be accepted.

- The sponsor is sole responsible for the correct designation of the documents on the form and thus for a clear identification of the documents that have been submitted to Swissmedic for acknowledgement or approval of changes. Incorrect identification of the documents may lead to findings during an inspection.

- For submissions of changes, a letter will be issued by Swissmedic (“decision” letter in case of significant changes, acknowledgement letter in case of other changes). For reporting, Swissmedic will send an acknowledgement by e-mail, with reference to the corresponding submission form.

3 Changes during the conduct of a clinical trial (amendments) (Art. 34 ClinO)

All changes in the documents as listed in ClinO Annex 4, 1.2 – 1.7 and 2.2. – 2.7 have to be submitted to Swissmedic.

Significant changes must be submitted to Swissmedic together with a rationale from the Sponsor (to be entered under point 2 on the form Submission of Changes to a Clinical Trial and Answer to Conditions). The amendments cannot be implemented before the approvals of both Swissmedic and the Ethics Committee have been obtained. Exception: urgent safety measures may be implemented before Swissmedic approval.
The definition of significant changes that have to be submitted to Swissmedic is given in Art. 34 ClinO and below.

Other changes shall be sent to Swissmedic as soon as possible (Art. 34, para 5 ClinO).

4 Protocol Amendments related to the use and/or safety of the IMP

(Section 5 of the CTA dossier)

All protocol amendments must be submitted to Swissmedic. The changes related to the use and/or safety of the IMP or any other significant modification according to art. 34 paragraph 3 ClinO must be approved by Swissmedic prior to implementation (exception: urgent safety measures). For all other changes (art. 34 paragraph 5 ClinO) Swissmedic will send an acknowledgement of receipt.

Protocol modifications must be documented in a summary of changes and the updated protocol version submitted in a track change (ideally a color print) mode or with visible changes.

5 Changes to the pharmaceutical quality documentation (PQD) of the IMP

(Section 7 of the CTA dossier)

Changes to the PQD or the IMPD shall only be submitted if related to the clinical trial.

All changes to the PQD or IMPD related to the clinical trial have to be submitted to Swissmedic.

A guidance on the substantial changes that need to be submitted to Swissmedic can be found in the European guideline “Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (EMA/CHMP/QWP/545525/2017 chapter 9).

Guidance for the submission of a change to the PQD:

Important: Submission of at least one document showing the modifications with the old text struck through and the new text bold or underlined and bold is mandatory. It can be either the PQD/IMPD or the tabular overview. For more details see below.
1. **Tabular overview of changes**

A tabular overview including all modifications, with indication if substantial or not, has to be provided. This tabular overview of changes can be a separate document or it can be integrated in the amended document (PQD or IMPD). If this table is integrated in the amended document, it must be printed separately for each trial involved.

Example:

<table>
<thead>
<tr>
<th>Amendment name, version, date</th>
<th>Substantial?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Previous Document number</strong></td>
<td><strong>New Document number</strong></td>
</tr>
<tr>
<td>Chapter xy</td>
<td>Chapter xy new information</td>
</tr>
<tr>
<td>Previous information</td>
<td>Full text with changes in</td>
</tr>
<tr>
<td></td>
<td>Or</td>
</tr>
</tbody>
</table>

2. **CD-Rom:**
   - Form Submission of Changes to a Clinical Trial
   - Amended documents in Track Change Version
   - Amended documents Clean Version
   - Tabular overview of changes as depicted above if not already contained in the amended document itself.

3. **Paper Versions.**
   - Form Submission of Changes to a Clinical Trial, signed by applicant
   - **Full track change version** (color print)
     In case only a clean version can be submitted all changes have to be clearly visible in the tabular overview of changes.
     If the amendment concerns more than one trial, only one printout has to be provided.
   - **Tabular overview of changes with modifications clearly visible**
     Please provide a copy of the overview for each trial concerned by the submission.

4. **Quality defects of IMPs**

Quality defects of IMPs have to be submitted to Marketing Surveillance (MS) of Swissmedic (www.swissmedic/human medicines/market surveillance/quality defects and batch recalls) and not to the Division Clinical Trials. During the Quality defect assessment you will be informed if changes to the study documentation is requested. Changes to the IMPD due to a quality defect, have then to be submitted to Swissmedic Division Clinical Trials, as well as the "closing correspondence" between MS Swissmedic and the Sponsor. The submission has to be sent with a submission of change form.

Please be aware that OOSs (out of specifications) have to be submitted to MS as a quality defect.
6 Changes to Study Medication Labels
(Section 9 of the CTA dossier)

Changes of the IMP-name have to be submitted to Swissmedic for approval. All other changes to the study label shall be submitted for information only.

7 Updated Investigator’s Brochure (IB)
(Section 6 of the CTA dossier)

The updated IB needs to be submitted until the final clinical study report is available. The reference safety information (RSI) in the IB should fulfil the requirements according to the “Q&A document – Reference Safety Information” dated November 2017 and the RSI cover note dated March 2018 of the Clinical Trial Facilitation Group CTFG (published on the HMA – CTFG website (www.hma.eu)). The changes to the IB as compared to the previously approved version must be documented in a summary of changes as shown in the model below and the updated version shall be submitted in track change mode or with visible changes.

Moreover, it must be indicated if, and to what extent, the risk/benefit analysis of the trial substance has changed. Should any measures have been taken on the basis of the new analysis, these should also be described.

Model: summary of changes

<table>
<thead>
<tr>
<th>section</th>
<th>Old text</th>
<th>New text</th>
<th>Rational for change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Original text to be changed in this section.</td>
<td>Original text to be changed in this section</td>
<td>Reason for changes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to be changed in this section with visible changes.</td>
<td></td>
</tr>
<tr>
<td>1.1</td>
<td>Original text</td>
<td>Original text</td>
<td>New information</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Added text</td>
<td></td>
</tr>
<tr>
<td>1.2</td>
<td>Original text to be deleted</td>
<td>Deleted text</td>
<td>Reason for deletion</td>
</tr>
</tbody>
</table>

8 Change of Sponsor / Sponsor Name or Address / other administrative changes
(Section 2 of the CTA dossier)

Swissmedic’s authorisation to perform a clinical trial cannot be transferred from a sponsor to another one. If a new sponsor takes over a clinical trial that has already been authorised for another sponsor, he must ask Swissmedic for a new authorisation. For this purpose, the new sponsor must complete the form Administrative Changes (including date and signature).

The completed form must be sent to Swissmedic at least 30 days prior to the date of take-over of the sponsorship. The submission must include a statement (signed and dated) of the previous sponsor that he gives up the sponsorship of the clinical trial.

In case of change of sponsor name or address, the form needs to be submitted as described above.

For a change of sponsor or sponsor name or a change of sponsor address involving a change of country, Swissmedic will issue an authorisation for the new sponsor or sponsor with new name or address, respectively and withdraw the previous authorisation.
A change of sponsor domicile within a country will be acknowledged only by e-mail.

Trial documents that have to be modified due to the change of sponsorship / change of sponsor name or address (protocol, labels, etc.) must be sent to Swissmedic according to ClinO annex 4.

Other administrative changes such as change of sponsor’s contact person or email-address/phone, contact for information/scientific questions or other should to be notified with the form Administrative Changes and will be acknowledged by e-mail.

9  Change Swiss Representative/ Representative Name or Address /
   other administrative changes
   (Section 2 of the CTA dossier)

If a new Swiss representative takes over responsibilities, Swissmedic must be informed.

For this purpose, the sponsor must complete the form Administrative Changes (including date and signature).

The completed form must be sent to Swissmedic at least 30 days prior to the date of change of the Swiss representative.

The same applies for change of Swiss representative name or address.

Swissmedic will confirm by e-mail that it has taken note of the change of sponsor representative / sponsor representative name or address.

Other administrative changes such as change of sponsor representative’s contact person or email-address/phone, contact for information/scientific questions or other should to be notified with the form Administrative Changes and will be acknowledged by e-mail.

10  Safety reporting in clinical trials of the categories B and C (Art. 37 ClinO)

Urgent safety and protective measures in clinical trials of the categories B and C must be taken immediately, without waiting approval by Swissmedic. They must be reported within 7 days to Swissmedic by the Sponsor.

Detailed information on safety measures including urgent safety measures, SUSARs or Annual Safety Report can be found on the Swissmedic website under “Safety measures in clinical trials”.

11  Premature discontinuation / Trial interruption

The sponsor must report a premature discontinuation or interruption of a clinical trial to Swissmedic, stating the reasons for the discontinuation or interruption.

The reporting timeline is 15 days (Art. 38 para. 2 ClinO). If a trial is stopped prematurely for safety-relevant reasons, Swissmedic must be informed within 7 days (Art. 37 para. 1 ClinO).

A final clinical study report (further details below) must be submitted.
12 Beginning and end of the trial

The **beginning** of the trial is considered as the “first subject first visit” for study purposes in Switzerland. The sponsor must report the beginning of the clinical trial to Swissmedic within 30 days. No acknowledgement of receipt will be sent.

The **end** of the trial is considered to be the ‘last subject last visit’ of the last open centre in Switzerland, unless differently defined in the trial protocol. The sponsor must report the end of a clinical trial to Swissmedic.

The timeline for reporting the end of the study is **90 days** (Art. 38 para. 1 ClinO).

A final clinical study report (further details below) must be submitted.

For international trials, Swissmedic accepts the international end date of the trial as the reference date for submitting the final report. Therefore, in order to determine the time limit that will be applied, Swissmedic must also be informed (in addition to the date on which the trial ends in Switzerland) on the date of international trial end.

13 Final clinical study report

A final clinical study report on the whole study must be submitted in line with Art 38 para. 5 of the ClinO within **1 year** of trial end or premature discontinuation.

Swissmedic has not published any guidelines on the formal requirements for the final report; however the ICH E3 guidelines (Structure and content of clinical study reports) should be followed. The final report should adequately summarize the data collected in the clinical trial.

The complete report without annexes (corresponding to chapters 1-15 of ICH E3) and a synopsis shall be submitted on CD and the synopsis shall additionally be submitted as a hard copy.

For international clinical trials which did not include subjects in Switzerland, no submission of the report or a synopsis is needed.

In the case of international trials that last longer than the participation of the Swiss centres, the final report should be submitted within **1 year of the end of the international trial** (Art. 38 para. 5 ClinO).
## Change history

<table>
<thead>
<tr>
<th>Version</th>
<th>Valid and binding as of:</th>
<th>Description, comments</th>
<th>Author’s initials</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.0</td>
<td>17.01.2020</td>
<td>Inclusion of information on quality defect reporting (formerly included in the FAQ document), change of FPFV acknowledgement procedures, clarifications, correction of links</td>
<td>hch</td>
</tr>
<tr>
<td>7.0</td>
<td>20.12.2018</td>
<td>Updates to submission of PQD changes, clarifications, corrections</td>
<td>hch</td>
</tr>
<tr>
<td>6.0</td>
<td>10.09.2018</td>
<td>Replacement of the forms change of sponsorship and change of Swiss representative by the form administrative changes</td>
<td>hch,jaf</td>
</tr>
<tr>
<td>5.0</td>
<td>01.06.2018</td>
<td>Inclusion of additional information on requirements for reference safety information and for reporting of study start; clarifications</td>
<td>hch</td>
</tr>
<tr>
<td>04</td>
<td>05.05.2017</td>
<td>Clarifications for submission requirements</td>
<td>hch,jaf</td>
</tr>
<tr>
<td>03</td>
<td>15.01.2017</td>
<td>New submission requirements with introduction of two new submission forms, clarifications</td>
<td>hch,gav,jaf</td>
</tr>
<tr>
<td>02</td>
<td>25.01.2016</td>
<td>New order of chapters for changes and reporting clarifications and corrections</td>
<td>hch</td>
</tr>
<tr>
<td>01</td>
<td>26.06.2015</td>
<td>Document belongs to new process (new QM-Ident)</td>
<td>hch</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Old: BW101_20_001e_AL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>New: BW101_10_003_AA</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clarification concerning submission of some changes / Introduction of the new form Change of Swiss Representative</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>30.04.2015</td>
<td>Inclusion of guidance for the submission of a change to the pharmaceutical quality documentation and to the Investigator’s Brochure / inclusion of information on change of sponsor and change of sponsor representative / clarifications for Clinical Study Report</td>
<td>hch</td>
</tr>
<tr>
<td>11</td>
<td>27.11.2014</td>
<td>Clarifications of submission requirements</td>
<td>hch</td>
</tr>
<tr>
<td></td>
<td>30.07.2014</td>
<td>New change history inserted in the document, dropdown field inserted in the header</td>
<td>wis</td>
</tr>
</tbody>
</table>